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Abstract
The ASBMT Clinical Case Forum (CCF) was launched in 2014 as an online secure tool to 
enhance interaction and communication among hematopoietic cell transplantation (HCT) 
professionals worldwide through the discussion of challenging clinical care issues. After 14 
months, we reviewed clinical and demographical data on cases posted in the CCF from 1/29/2014 
to 3/18/2015. A total of 137 cases were posted during the study period. Ninety-two cases (67%) 
were allogeneic HCT, 29 (21%) autologous HCT and in 16 (12%) the type of transplant (auto vs. 
allo) was still under consideration. The diseases most frequently discussed included non-Hodgkin 
lymphoma (NHL; n = 30, 22%), acute myeloid leukemia (AML; n = 23, 17%) and multiple 
myeloma (MM; n = 20, 15%). When compared with the US transplant activity reported by the US 
Department of Health and Human Services, NHL and acute lymphoblastic leukemia cases were 
overrepresented in the CCF while myeloma was underrepresented (P < 0.001). A total of 259 
topics were addressed in the CCF with a median of two topics/case (range 1-6). Particularly 
common topics included whether transplant was indicated (n = 57, 41%), conditioning regimen 
choice (n = 44, 32%), and post-HCT complications after day 100 (n = 43, 31%). The ASBMT 
CCF is a successful tool for collaborative discussion of complex cases in the HCT community 
worldwide and may allow identification of areas of controversy or unmet need from clinical, 
educational and research perspectives.
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 INTRODUCTION
Hematopoietic cell transplantation (HCT) is a life-saving procedure for patients with high-
risk malignant or non-malignant hematologic disorders, or solid tumors. However, HCT 
carries significant risk of treatment-related morbidity and mortality (TRM) (1).
There are multiple opportunities for highly complex clinical decision-making along the HCT 
trajectory, from patient selection (e.g. interpretation of disease and patient-related factors 
influencing candidacy for HCT), to HCT approach (e.g. conditioning regimen, graft source 
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and manipulation, donor selection), or HCT complications (e.g. management of graft-
versus-host disease [GVHD], organ toxicity, infections, relapse, late effects). HCT-related 
technology and practice are continually evolving and improving, adding additional 
complexity to clinical decisions (2). Although numerous clinical guidelines and evidence-
based consensus statements have been published on these and other topics (3-13), cases 
featuring unique characteristics emerge every day in clinical practice. Not surprisingly, 
previous research has documented significant variation in clinical decision-making among 
transplant health care professionals, including patient referral to transplant centers, 
supportive care practice and management of immunosuppression to prevent and/or treat 
GVHD (14-17). Additionally, evidence-based reviews and other published treatment 
guidelines are inherently limited by lags in time to publication, which may result in months 
to years from conception to dissemination following peer review and editing.
Because HCT is a field characterized by significant risk of procedure-related morbidity and 
mortality, significant resource utilization, and variation in practice among trained 
professionals (18, 19), it represents an ideal environment for application of a learning 
healthcare system. As defined by the Institute of Medicine, “A learning healthcare system is 
[one that] is designed to generate and apply the best evidence for the collaborative 
healthcare choices of each patient and provider; to drive the process of discovery as a natural 
outgrowth of patient care; and to ensure innovation, quality, safety, and value in health care” 
(20, 21). While several resources within the field of HCT already exist to support a learning 
healthcare system, such as the Center for International Blood and Marrow Transplant 
Research (CIBMTR), the National Marrow Donor Program (NMDP), the American Society 
for Blood and Marrow Transplantation (ASBMT) and the Foundation for the Accreditation 
of Cellular Therapy (FACT), there are relatively few widely available resources to assist in 
daily decision making in clinical practice, and help the HCT community learn continuously 
from the experience of other clinicians in a relatively real-time fashion.
We hypothesized that a secure, online forum for discussing challenging clinical care issues 
within the field of HCT would be significantly utilized by the global HCT community, and 
that discussions within this forum would reflect variation among HCT professionals’ 
approaches to clinical care issues. In addition, discussions on the forum could potentially 
identify areas of controversy or areas of unmet need, not only in the clinical sense but also 
from an educational perspective. We also hypothesized that this forum would allow 
relatively real-time discussion and dissemination of contemporary practice patterns, without 
the delays associated with more formal and traditional publications. We now describe the 
experience of the ASBMT Clinical Case Forum (hereafter referenced as “the CCF” or “the 
ASBMT CCF”), a secure, online forum for the discussion of challenging HCT cases.
 METHODS
 Clinical Case Forum Development
ASBMT, through the Committee on Education and the Subcommittee on Web-based 
Learning, developed a secure, online forum for discussion of challenging clinical care issues 
(www.asbmt.medting.com). The forum was named the ASBMT Clinical Case Forum 
(ASBMT CCF). The software for the ASBMT CCF was made available through 
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collaboration with Best Doctors (Boston, MA), a company that specializes in remote 
medical consultations. The ASBMT CCF contains several features that facilitate secure and 
informative case submission and discussions. Participants must login securely prior to 
accessing site content. Once granted access to the site, participants may submit a case, read 
others’ cases and comments, and submit new comments on cases. To submit a case, 
participants enter a title and free text clinical data into a submission dialog box, in addition 
to optional inclusion of de-identified pathology slides, radiological images (supported 
through the integrated MedViewer imaging platform), photographs (e.g. dermatologic 
lesions), and other ancillary data (Supplementary Figure 1). The site is monitored for 
uploading of any information that has not been de-identified. Participants can also assign 
cases to one or more topic groups, enabling cases to be easily searched using keywords. 
Once posted, cases may receive subsequent comments from other CCF participants, with 
comments appearing sequentially, directly below the case submission (Supplementary File 
2). The CCF software supports translation to other languages, allowing global participation 
and facilitating the development of the CCF into an international initiative. This feature is 
particularly important in transplantation, as a global transplant community provides a 
platform for users in less-developed countries with less mature transplant programs to 
connect with more experienced transplant teams.
In February 2014, coincident with the annual BMT Tandem Meetings, the ASBMT CCF 
was launched as an ASBMT member benefit. For the first 6 months, access to the CCF was 
also granted to non-members who had attended the annual meeting. In the year that 
followed, the CCF has been available to physicians, nurses, advanced practitioners, 
pharmacists, and trainees for case posting and commentary.
 Data abstraction and definitions
After the ASBMT CCF was open for approximately a year, the ASBMT Committee on 
Education reviewed the data associated with cases and comments posted through 3/18/2015. 
IRB approval was obtained to conduct this minimal-risk research. One data abstractor 
(WAW) summarized the case topic and assigned the case to one or more categories 
associated with the HCT process. A second data abstractor (PB) reviewed these 
determinations and additionally determined the urgency of the case and dates of comments. 
Urgency was determined based on clinical information posted and was defined as a case 
needing an answer in < 72h, based on the opinion of the reviewers. A third investigator 
(MAP) reviewed all information and was available to adjudicate in case of any 
discrepancies. US transplant activity for the year 2013 reported in the Health Resources and 
Service Administration of the US Department of Health and Human Services (http://
bloodcell.transplant.hrsa.gov/RESEARCH/Transplant_Data/US_Tx_Data/Data_by_Disease/
national.aspx) was used to compare the distribution of diseases in the CCF with the actual 
HCT activity across the country.
 Objectives and Statistical Analysis
The primary objective of the study was to describe the cases reported to the CCF during the 
study period. A secondary objective was to identify areas of unmet needs and controversial 
topics that would potentially benefit from future educational or consensus approaches. 
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Fisher’s exact test was used to compare both the disease frequency and the frequency of 
each transplant type in the CCF compared with the US transplant activity reported by the US 
Department of Health and Human Services. All other statistics were descriptive.
 RESULTS
 Demographics
Demographic and disease information are summarized in Table 1. As of March 18, 2015, 
137 cases had been posted on the ASBMT CCF (Figure 1). Most cases (n = 92, 67%) 
referred to allogeneic HCT (allo-HCT), while 29 (21%) concerned autologous HCT (auto-
HCT). In 16 additional cases, the type of transplant was still under consideration. When we 
compared the distribution of the 121 CCF cases where the HCT approach was defined with 
the 2013 US HCT activity, allo-HCT was overrepresented in the CCF (76% in the CCF vs. 
43% in the US transplant activity). Consequently, auto-HCT was less present in the CCF 
than in the US HCT activity (24% vs. 57%, respectively; overall p value < 0.001).
Median age at HCT for the whole cohort was 53 years (range 3-82). The vast majority of the 
cases (n = 131, 96%) referred to adult patients, mostly to patients aged 41-60 (n = 49, 36%). 
Only 6 cases of patients aged 18 or younger were posted. Most transplantable diseases were 
represented, though relatively few cases referenced non-malignant conditions or solid 
tumors, again reflecting the common etiologies in adult patients. The most commonly 
represented diseases were non-Hodgkin lymphoma (NHL; n = 30, 22%), acute myeloid 
leukemia (AML; n = 23, 17%) and multiple myeloma (MM; n = 20, 15%). When compared 
with the US transplant activity, NHL and acute lymphoblastic leukemia (ALL) cases were 
overrepresented in the CCF while MM was underrepresented (overall P < 0.001) (Figure 2).
Regarding transplant topics, 259 topics were addressed in the CCF with a median of two 
topics/case (range 1-6). Particularly common topics included whether transplantation was 
indicated (n = 57, 41%), conditioning regimen choice (n = 44, 32%), and post-transplant 
complications after day 100 (n = 43, 31%).
 Cases in most frequent diseases
Detailed information on transplant topics according to underlying disease is summarized in 
Table 2. Supplemental Table 1 includes synopses of the 137 cases submitted to the ASBMT 
CCF as of March 18, 2015.
 Acute leukemias—A total of 23 cases (17%) including patients with AML were 
posted, all but one of them regarding allo-HCT. AML cases addressed 43 topics with a 
median of 1 topic/case (range 1-6). The most frequent topics in AML were conditioning 
regimen (n = 11, 48%) and whether transplantation should be recommended (n = 9, 39%). 
For ALL, 19 cases (14%) were posted in the CCF. In contrast to AML, the most frequent 
questions were about post-transplant relapse (n = 10, 53%), either its prevention (n = 5), 
treatment (n = 3) or both (n = 2).
Of the 12 cases about conditioning regimen in acute leukemias, six were related to the 
intensity of the regimen (myeloablative conditioning [MAC] vs. reduced intensity 
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conditioning/nonmyeloablative conditioning [RIC/NMA]) in patients with advanced age or 
comorbidities. Of note, all but one of the cases about conditioning regimen in acute 
leukemia concerned patients with AML.
Five of the 20 cases (25%) about relapse in leukemia discussed the use of post-transplant 
therapy either for relapse prevention or in the setting of minimal residual disease. Most of 
them referred to the use of tyrosine kinase inhibitors in Philadelphia chromosome positive 
(Ph+) ALL, but the use of prophylactic donor leukocyte infusion (DLI) and hypomethylating 
agents in AML were also discussed.
When comparing CCF data with the US transplant activity in 2013, the proportion of AML 
cases in the CCF was similar to the actual transplants performed (17% vs. 16%, 
respectively), whereas, when we examined allo-HCT cases specifically, the proportion of 
AML cases in the CCF was lower than that of actual transplants performed (24% vs. 36%, 
respectively). For ALL, there were proportionally more cases discussed in the CCF than 
actual cases in the registry (14% vs. 6%, respectively). Similarly, for allo-HCT, the activity 
for ALL in the CCF was slightly higher (17% in the CCF vs. 13.5% in the US registry).
 Lymphoid malignancies—Thirty-eight cases (28%) included patients diagnosed with 
lymphoid malignancies. The most common histologies were diffuse large B cell lymphoma 
(n = 9, 24%), mantle cell lymphoma (n = 6, 16%), Hodgkin lymphoma (n = 5, 13%) and 
follicular lymphoma (n = 4, 10%), although 11 other histologies were represented. Sixteen 
cases (42%) referred to allo-HCT and 12 (32%) to auto-HCT. In 10 cases (26%) the choice 
of auto-HCT or allo-HCT was still under consideration.
The most frequent topics in lymphoid malignancies were related to the selection of 
conditioning regimen (n = 18, 48%), with most queries arising in the allo-HCT setting (n = 
15). Fourteen cases (37%) addressed questions about whether transplant should be 
recommended. Most of these cases questioned whether allogeneic or autologous 
transplantation should be used as upfront consolidation therapy in high-grade NHL or in 
heavily pretreated low-grade NHL.
When comparing CCF data with the US transplant activity in 2013, the proportion of 
Hodgkin lymphoma cases in the CCF was similar to that of actual transplants performed 
(4% vs. 5%, respectively), whereas for NHL, the activity in the CCF was slightly higher 
(22% in the CCF vs. 18% in the US registry). For Hodgkin lymphoma and NHL, there was a 
similar proportion of allo-HCT cases in the CCF when compared to the US transplant 
activity (0% vs. 2%, and 12% vs. 11%, respectively).
 Multiple myeloma and amyloidosis—Twenty cases (15%) included patients 
diagnosed with MM and amyloidosis, with 12 of them (60%) being cases of auto-HCT, 
although this percentage also reflects a higher number of questions about allo-HCT than one 
would expect based on practice patterns. The most frequent topic discussed in this group of 
patients was whether to recommend HCT (n = 12, 60%), followed by relapse (n = 9, 45%), 
either its prevention (n = 2, 10%), treatment (n = 4, 20%) or both (n = 3, 15%). There was a 
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lower proportion of HCT cases for MM and amyloidosis in the CCF when compared to the 
US transplant activity (15% vs. 34%, respectively).
 Urgent cases: Twenty cases (14%) were considered to require a response within 72 hours 
based on the reviewers assessment and were classified as urgent (Table 3). Eighteen of these 
cases (90%) discussed allo-HCT patients. The most frequent diseases included AML (n = 6, 
30%), ALL (n = 3, 15%) and NHL (n = 3, 15%). The majority of these urgent cases (n = 14, 
70%) referred to post-transplant complications, either early (n = 9, 64%) or late (n = 5, 36%) 
complications. Neurological symptoms and impaired consciousness accounted for at least 5 
of these urgent cases. Interestingly, hemophagocytic lymphohistiocytosis syndrome (HLH), 
a rare complication after HCT, was the topic of 3 cases. The typical reason for urgency was 
the unstable medical condition of the patient.
 DISCUSSION
The ASBMT CCF was launched in February 2014 to provide a secure, online forum for the 
discussion of challenging HCT cases. In the first year, 137 cases have been posted and 
commented on in the CCF. Based on the types of cases posted, a few general observations 
can be made. First, the ASBMT CCF appears to be successful in meeting a need in the HCT 
community for collaborative discussion and informed decision making regarding complex 
cases. The utilization of the ASBMT CCF has been significant, with the case and comment 
volume through March 2015 exceeding the pre-launch expectations of the ASBMT 
Committee on Education. Second, a review of the cases highlights specific diseases and 
questions that are recurrent throughout the posted cases and could represent topics for 
further development of clinical guidelines and learning tools. As expected by the higher 
level of complexity, cases on allo-HCT were more common than auto-HCT, in contrast to 
the incidence of the two procedures in usual practice. Importantly, in 12% of the cases, the 
recommended transplant approach itself (auto- vs. allo-HCT) was the topic, perhaps 
reflecting lack of consensus in the field for certain indications, or that specific cases do not 
necessarily fit well within existing guidelines. From a disease perspective, a wide range of 
the most common transplantable diseases was present in the CCF. However, there were some 
slight variations when compared with the US transplant activity. For instance, in the allo-
HCT setting, ALL was overrepresented in the CCF whereas AML was underrepresented. 
The questions also differed between AML and ALL, with more questions about HCT 
indication and conditioning regimen in AML, while relapse was the main topic in ALL. 
These observations may highlight areas for further study and intervention regarding usual 
practice in these diseases.
Several interesting trends were also identified in the cases that did not involve acute 
leukemias, with many questions also related to HCT indication and conditioning regimen. 
Post-transplant complications were also found in a high number of cases (48%). However, 
only a few of them referred to the most common causes of TRM in the allo-HCT setting: 
prevention and/or treatment of GVHD and diagnosis or management of opportunistic 
infections. In contrast, rare complications such as HLH or autoimmune hemolytic anemia 
(AIHA) were the topic of several cases. This finding highlights areas in which there is either 
a lack of data or knowledge, or both. Whereas multiple guidelines, courses and on-line 
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resources exist for the management of GVHD and infections for example, little is available 
for less frequent complications such as HLH. The ASBMT CCF may thus fill an important 
need for low-frequency and urgent complications following transplant.
Moving forward, we anticipate enhancements to the ASBMT CCF as well as secondary 
projects related to activity on the ASBMT CCF that can further our goal of leveraging the 
ASBMT CCF to foster a learning healthcare system within the field of HCT. First, while the 
ASBMT CCF has been well utilized in a short period of time, we recognize that a large 
segment of the HCT provider community, including expertise in many of the topics 
represented on the CCF, remains untapped. Furthermore, our review identified at least 15% 
of cases that required an answer in less than 72 hours, mostly due to the unstable medical 
condition of the patient or because they involved drug changes or dose adjustments that 
needed to be done almost in real time. While the ASBMT CCF does not intend to take the 
place of direct and timely consultation with appropriate experts, it is clear that timely 
responses will not only have a potential impact on patient outcomes, but also more 
importantly, as a learning tool foster greater engagement within the HCT community. To this 
end, we plan to develop a panel of case discussants with expertise in different areas of HCT 
who would be able to respond within 48 hours of a case being posted. The goal is to ensure 
that each case submitted receives prompt, robust, and substantive discussion, while 
maintaining the transparent and community-oriented environment that has been the hallmark 
of the ASBMT CCF to date.
Furthermore, by performing ongoing analyses of the types of cases posted to identify areas 
of unmet need, we hope to foster collaborations among CCF participants and potentially 
generate new research efforts or publications within the HCT community. Additional 
secondary applications of the ASBMT CCF are also envisioned. Data from the CCF may be 
used to develop surveys for the transplant community about current practices or preferences 
in particular areas of transplantation. Where substantial practice variation or controversy is 
found to exist, ASBMT may consider developing topical guidelines, consensus statements, 
reviews, or other educational efforts to assist the transplant community with these clinical 
challenges. ASBMT CCF cases may also be used as the basis for peer-reviewed “Ask the 
Expert” style case discussions in the transplant literature, or as the basis for oral case 
presentations and panel discussions at annual BMT Tandem meetings. As an example, the 
above mentioned differences in particular topics in AML and ALL should be taken into 
account when designing future guidelines and learning tools. Similarly, the identification of 
infrequent but relatively highly commented complications such as HLH and AIHA could 
serve as a starting point for the development of these tools. Several of these ideas are 
currently under consideration by the ASBMT Committee on Education.
In a broader sense, we hope that ASBMT CCF cases lead to further efforts towards 
systematic data collection and critical, evidence-based scrutiny of usual care practices within 
HCT. Additionally, areas of clear and prevalent controversy without any acceptable evidence 
basis could be used to inform ideas for future institutional or multicenter protocols, or 
CIBMTR studies.
Barba et al. Page 8
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Though the ASBMT CCF has only been open for about a year, utilization has been 
significant and continues to increase. We plan for improvements to the CCF to further enrich 
the participant experience. Most importantly, there are multiple opportunities in the future to 
leverage the ASBMT CCF to foster a learning healthcare system within the field of 
transplantation.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Cumulative number of cases posted on the ASBMT CCF
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Figure 2. 
Distribution of diseases in patients undergoing HCT reported in the CCF and in the US 
(2013)
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Table 1
Demographic and disease information for cases presented on the ASBMT CCF.
Case characteristic Total
n (%)
Auto-
HCT
n (%)
Allo-
HCT
n (%)
Transplant
approach not
defined
n (%)
TOTAL NUMBER OF PATIENTS 137 (100) 29 (21) 92 (67) 16 (12)
Age, years (%)
 ≤ 18 6 (4) 0 (0) 6 (7) 0 (0)
 19-40 37 (27) 7 (24) 27 (29) 3 (19)
 41-60 49 (36) 7 (24) 30 (33) 12 (75)
 >60 34 (25) 11 (38) 23 (25) 0 (0)
Unknown/not provided 11 (8) 4 (14) 6 (7) 1 (6)
Disease , n (%)
 Acute myeloid leukemia 23 (17) 1 (3) 22 (24) 0 (0)
 Acute lymphoblastic leukemia 19 (14) 1 (3) 16 (17) 2 (13)
 Myelodysplastic syndrome 14 (10) 1 (3) 13 (14) 0 (0)
 Non-Hodgkin lymphoma 30 (22) 12 (41) 11 (12) 7 (48)
 Hodgkin lymphoma 5 (4) 0 (0) 3 (3) 2 (13)
 Multiple myeloma and amyloidosis 20 (15) 12 (41) 4 (4) 4 (25)
 Chronic myeloid leukemia 10 (7) 0 (0) 10 (11) 0 (0)
 Othera 10 (7) 1 (3) 8 (9) 1 (6)
Not provided 6 (4) 0 (0) 6 (7) 0 (0)
Transplant topic, n (%)b
Indication for transplantation 57 (41) 16 (55) 35 (38) 6 (38)
Conditioning regimen 44 (32) 9 (31) 25 (27) 10 (63)
Graft source 19 (14) 1 (3) 5 (5) 13 (81)
Donor choice 27 (20) 0 (0) 15 (16) 12 (75)
GVHD prophylaxis 11 (8) 0 (0) 11 (12) 0 (0)
Relapse prevention (including pre-HCT chemotherapy) 33 (24) 8 (28) 21 (23) 4 (25)
Early (< D+100) post-transplant complications 25 (18) 5 (17) 20 (22) 0 (0)
Late (≥ D+100) post-transplant complications 43 (31) 4 (14) 38 (41) 1 (6)
  Post-transplant infectionc 5 (4) 2 (7) 3 (3) 0 (0)
  Post-transplant GVHDc 5 (4) 0 (0) 5 (5) 0 (0)
  Post-transplant relapsec 28 (20) 2 (7) 25 (27) 1 (6)
  Other post-transplant toxicity / complicationc 33 (24) 5 (17) 28 (30) 0 (0)
Abbreviations: n, number; Auto, autologous; Allo, allogeneic; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation.
Footnotes:
a
: “other” includes: Myelofibrosis (n=2), Diamond Blackfan Anemia(n=1), aplastic anemia (n=1), germ cell tumor (n=1), osteopetrosis (n=1), 
chronic lymphocytic leukemia (n=1), B- and T- cell prolymphocytic leukemia (n=1, each), donor (n=1);
b
: Since one case may address more than one topic, the total number of topics exceeds the number of patients;
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c
: specific subtypes of early and late post-transplant complications. Since some cases had questions about more than one subtype, the total number 
of comments may exceed the number of comments on the topic ‘Early / Late post-transplant complications’.
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